Related Experiment Video

Updated: Jun 25, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K

Glyoxalase System in Breast and Ovarian Cancers: Role of MEK/ERK/SMAD1 Pathway

Muhanad Alhujaily1

  • 1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha 61922, Saudi Arabia.

Biomolecules
|May 24, 2024
PubMed

Insights

The glyoxalase system (GLO1/GLO2) detoxifies methylglyoxal, and its dysregulation links to cancer. Targeting these pathways and the MEK/ERK/SMAD1 cascade offers potential for novel cancer diagnostics and therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The glyoxalase system (GLO1/GLO2) detoxifies cytotoxic methylglyoxal (MGO) produced during glycolysis.
  • Dysregulation of the glyoxalase system and the MEK/ERK/SMAD1 signaling pathway are implicated in cancer development, progression, and metastasis.
  • The roles of GLO1 and GLO2 are complex and context-dependent in various cancer types, including ovarian and breast cancer.

Purpose of the Study:

  • To review the interconnected roles of the glyoxalase system and the MEK/ERK/SMAD1 pathway in cancer.
  • To highlight the involvement of these systems in drug resistance and their clinical significance.
  • To discuss the need for biomarkers and therapeutic strategies, considering pathway crosstalk and context-dependent effects.

Main Methods:

  • Literature review of studies on the glyoxalase system, MEK/ERK/SMAD1 pathway, and their roles in cancer.
  • Analysis of research on GLO1 and GLO2 expression and function in different cancer contexts.
  • Examination of evidence linking these pathways to cancer aggressiveness, metastasis, angiogenesis, and drug resistance.

Main Results:

  • Altered GLO1 expression is linked to cancer aggressiveness, while GLO2 has context-dependent pro- or anti-apoptotic effects.
  • The glyoxalase system interacts with the MEK/ERK/SMAD1 signaling cascade, influencing tumorigenesis and metastasis.
  • Biomarkers like the RAGE-ligand pathway in ovarian cancer are emerging, and therapeutic targeting shows promise but faces challenges.

Conclusions:

  • The glyoxalase system and MEK/ERK/SMAD1 pathway are critical in cancer, with complex interactions influencing disease progression.
  • Understanding these molecular intricacies is vital for developing effective cancer diagnostics and personalized therapies.
  • Despite challenges from context-dependent effects, targeting these pathways offers hope for improved cancer treatment strategies.
Keywords:
GLO1 and GLO2 enzymesbreast and ovarian cancerglyoxalase systemmethylglyoxal (MGO)

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.0K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K